TuHURA Biosciences Inc(HURA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.53 | Insider Own | 34.62% | Shs Outstand | 63.7M | Perf Week | 2.49% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | -9.35% | Insider Trans | - | Shs Float | 41.7M | Perf Month | -1.9% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.14 | Inst Own | 14.4% | Short Float | 14.25% | Perf Quarter | -5.07% |
| Income | -0.03B | P/S | - | EPS this Y | 11.75% | Inst Trans | -2.36% | Short Ratio | 22 | Perf Half Y | -8.04% |
| Sales | 0.00B | P/B | 7.2 | EPS next 5Y | 36.24% | ROA | -92.29% | Short Interest | 5.94M | Perf YTD | 172.23% |
| Book/sh | 0.29 | P/C | 131.28 | EPS past 3/5Y | 87.54% 81.38% | ROE | -161.39% | 52W High | -39.94% ($3.43) | Perf Year | -15.92% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | -137.37% | 52W Low | 402.44% ($0.41) | Perf 3Y | -98.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 84.8% | Gross Margin | - | Volatility(W/M) | 8.71% 7.67% | Perf 5Y | -99.87% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.18 | EPS Q/Q | 32.55% | Profit Margin | - | RSI (14) | 53.21 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.18 | Sales Q/Q | - | SMA20 | 6.53% ($1.93) | Beta | -0.24 | Target Price | $7.87 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/8/14 | SMA50 | 1.72% ($2.03) | Rel Volume | 1.1 | Prev Close | $1.99 |
| Employees | 22 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | 8.68% - | SMA200 | 4.82% ($1.97) | Avg Volume(3M) | 0.27M | Price | $2.06 |
| IPO | 2013/2/22 | Option/Short | No/Yes | Trades | 1413 | Volume | 298,098 | Change | 3.52% |
🧬 This is a clinical-stage immuno-oncology biotech developing combination therapy pipelines that stimulate both innate and adaptive immunity. Its lead candidate is a combination therapy targeting advanced Merkel cell carcinoma, and it is also advancing an antibody candidate targeting acute myeloid leukemia. The company has a history of expanding its pipeline through past mergers and acquisitions, and is a small biotech focused on rare oncology indications.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
HURA has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #337 of 594 in the industry
Based on market cap of $131M.
MOLN#334 Molecular Partners AG ADR $135M PER - 
SPRB#335 Spruce Biosciences Inc $135M PER - 
CDXS#336 Codexis Inc $134M PER - HURA#337 TuHURA Biosciences Inc $131M PER - 
HUMA#338 Humacyte Inc $131M PER - 
FAQ
What kind of company is HURA?
HURA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HURA?
The market cap of HURA is approximately $131M, ranking 4,324 within its sector.
What is the 52-week high and low for HURA?
HURA has recorded a 52-week high of $3.43 and a low of $0.41.
